Professor of Radiation Oncology, University Tex SW Dallas
Radiation Oncology
Dr. Hak Choy, MD
|
|
Give Review
Hak Choy, MD is an expert in the field of Radiation Oncology. He received 3 awards: "America's Top Doctors", "America's Top Doctors for Cancer" and "CMS Meaningful Use Stage 1 Certification". Hak Choy is a published doctor and has 86 publications published. The lastest was: 'A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Canc...' Dr. Hak Choy accepts Medicare.
Publications
- A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Canc...
- Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: A systematic review of completed and ong...
- Stereotactic Radiation Therapy of Renal Cancer Inferior Vena Cava Tumor Thrombus.
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage I...
- Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer.
- Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors following stereotactic radiation therapy for early-stage non-small cell lung cancer.
- EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: A secondary analysis of RTOG 0324.
- Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial.
- Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer.
- Localization accuracy and immobilization effectiveness of a stereotactic body frame for a variety of treatment sites.
- A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group G05-92.
- Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favo...
- Decline in Tested and Self-Reported Cognitive Functioning After Prophylactic Cranial Irradiation for Lung Cancer: Pooled Secondary Analysis of Radiation Therapy Oncolo...
- Effect of PF-02341066 and radiation on non-small cell lung cancer cells.
- Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012.
- Phase II Study of Accelerated High-Dose Radiotherapy With Concurrent Chemotherapy for Patients With Limited Small-Cell Lung Cancer: Radiation Therapy Oncology Group Pr...
- Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer.
- Stereotactic ablative body radiation therapy for tumors in the lung in octogenarians: a retrospective single institution study.
- Cooperative group research endeavors in small-cell lung cancer: current and future directions.
- Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?
- The antiangiogenic agent SU5416 down-regulates phorbol ester-mediated induction of cyclooxygenase 2 expression by inhibiting nicotinamide adenine dinucleotide phosphat...
- Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress.
- Chemotherapy and irradiation interaction.
- Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
- Efficacy of high dose per fraction radiation for implanted human prostate cancer in a nude mouse model.
- Adjuvant and neoadjuvant treatments for NSCLC.
- Consideration of Dose Limits for Organs at Risk of Thoracic Radiotherapy: Atlas for Lung, Proximal Bronchial Tree, Esophagus, Spinal Cord, Ribs, and Brachial Plexus.
- Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib.
- Stereotactic body radiation therapy for thoracic cancers: recommendations for patient selection, setup and therapy.
- A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary anal...
- Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization.
- Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy f...
- DNA-PKcs-dependent modulation of cellular radiosensitivity by a selective cyclooxygenase-2 inhibitor.
- SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor.
- The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells.
- COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer.
- Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer.
- Non-small cell lung cancer and central nervous system metastases: should we be using prophylactic cranial irradiation?
- Potential for combined modality therapy of cyclooxygenase inhibitors and radiation.
- Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer.
- Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model.
- A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.
- Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer.
- Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?
- Cetuximab in combination therapy: from bench to clinic.
- Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
- Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study.
- Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.
- Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.
- Dosimetric uncertainties of three-dimensional dose reconstruction from two-dimensional data in a multi-institutional study.
- Combined modality therapy for non-small cell lung cancer, past, present, and future.
- 4-Dimensional conformal radiation therapy: image-guided radiation therapy and its application in lung cancer treatment.
- Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer.
- Primary Analysis of a Phase II Randomized Trial Radiation Therapy Oncology Group (RTOG) 0212: Impact of Different Total Doses and Schedules of Prophylactic Cranial Irr...
- Chemoradiation in NSCLC: focus on the role of gemcitabine.
- A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
- Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer.
- Rationale for investigation of epidermal growth factor receptor inhibitors in definitive treatment of locally advanced non-small cell lung cancer and head and neck can...
- Locally advanced NSCLC: current state of the art, treatment and future directions.
- Sustained metaphase arrest in response to ionizing radiation in a non-small cell lung cancer cell line.
- Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation...
- Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-...
- A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of R...
- Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation ...
- Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.
- Concurrent chemoradiotherapy for inoperable stage III non-small-cell lung cancer.
- Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells.
- Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
- Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells.
- Summary of presentations from the 11th targeted therapies for lung cancer meeting: radiation oncology.
- Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant.
- Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer.
- Current status and future prospects for satraplatin, an oral platinum analogue.
- Prophylactic cranial irradiation with combined modality therapy for patients with locally advanced non-small cell lung cancer.
- Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cel...
- Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.
- Stereotactic body radiation therapy for inoperable early stage lung cancer.
- Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modalit...
- The influence of gender, race, and marital status on survival in lung cancer patients: analysis of Radiation Therapy Oncology Group trials.
- Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-...
- Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small-Cell Lung Cancer: RTOG 0324.
- A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carbo...
- RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy ...
- Satraplatin: an orally available platinum analog for the treatment of cancer.
- RTOG current clinical trials in lung cancer. Overview.
Schools
Univ Of Tx Med Branch Galveston
University Tx Health Science Center
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
Education
-
Ohio State University Hospital -
University of Texas Medical Branch
Hospital
-
University of Texas Southwestern Medical Center -
Children's Health System of Texas -
Parkland Health & Hospital System
Drug Facts
| NPI NUMBER | 1487616462 | |
| NPPES Provider LastName | CHOY | |
| NPPES Provider FirstName | HAK | |
| NPPES Provider ZIPCode | 753907208 | |
| NPPES Provider State | TX | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 15.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1487616462 |
| Last Name Of The Provider | CHOY |
| First Name Of The Provider | HAK |
| View All |
Similar Doctors
|
|
Dr. Arve W. Gillette, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas L. Borok, MD |
|
|
Dr. Granger R. Scruggs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth Westover, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kimberly M. Thomas, MD |